APA Blogs
36 Results
What APA Is Doing for You: Update on Clozapine REMS
- By Saul Levin, M.D., M.P.A., FRCP-E, FRCPsych
In November 2021, the Food and Drug Administration (FDA) instituted a new Clozapine Risk Evaluation and Mitigation Strategy (REMS) to monitor prescribing and dispensing of the drug, which is used to treat schizophrenia. The new REMS led to confusion for manufacturers, pharmacies, prescribers, and patients. Some clinicians stopped prescribing the already underutilized drug, and some pharmacies stopped dispensing it. This chaotic situation led the FDA to stop enforcing certain requirements of the REM for 90 days.
Women’s History Month: Spotlighting the Women Leaders of APA
March is Women’s History Month and we’re highlighting several women currently leading the organization: APA President Vivian Pender, M.D., President-Elect Rebecca W. Brendel, M.D., J.D., and Assembly Speaker Mary Jo Fitz-Gerald, M.D., M.B.A.
APA Members: Remember to Vote by Jan. 31
Because of changes to the election guidelines in effect this year that are designed to even the playing field, APA helped to produce some additional materials about the candidates.
The Mental Health Needs of Those Impacted by the End of the War in Afghanistan Continue: Resources for Ongoing Efforts
As tens of thousands of evacuees from Afghanistan continue to be resettled across the U.S. this winter, anticipating and responding to their mental health needs remain paramount.
APA Ethics Committee Issues Opinion on the Spread of Disinformation
"When speaking publicly about a pandemic, therefore, it is particularly incumbent upon psychiatrists to honestly and responsibly share factual information,” states a new opinion from the American Psychiatric Association’s Ethics Committee. “Disseminating falsehoods about a pandemic disease such as COVID-19, including misleading information about scientifically supported public health protocols or vaccines, is unethical.”